52
Participants
Start Date
October 20, 2022
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2028
Parenteral Treprostinil
Parenteral treprostinil will be administered per schedule specified in the arm description.
Oral Treprostinil
Oral treprostinil will be administered per schedule specified in the arm description.
University of Rochester Medical Center, Rochester
Temple Hospital, Philadelphia
Carilion Clinic, Roanoke
University of North Carolina at Chapel Hill, Chapel Hill
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
Prisma Health, Greenville
Georgia Clinical Research, Austell
USF, Tampa
The Ohio State University Wexner Medical Center, Columbus
University of Cincinnati, Cincinnati
Indiana University Health North Hospital, Indianapolis
Community Health Network, Indianapolis
Henry Ford Health System, Detroit
Northwestern Memorial Hospital, Chicago
University of Nebraska Medical Center, Omaha
Integris Baptist Medical Center, Oklahoma City
Oklahoma Heart Institute, Tulsa
UT Southwestern Medical Center, Dallas
Banner University Medical Center (University of Arizona), Phoenix
HonorHealth John C. Lincoln Medical Center, Phoenix
Cedars-Sinai Medical Center, Los Angeles
University of California San Francisco - Fresno, Fresno
University of California San Francisco Pulmonary, Critical Care, Allergy and Sleep Medicine, San Francisco
University of California Davis Medical Center, Sacramento
Hartford Hospital, Hartford
Brigham and Women's Hospital, Boston
Morristown Medical Center, Morristown
Lead Sponsor
Collaborators (1)
Lung Biotechnology PBC
INDUSTRY
United Therapeutics
INDUSTRY